Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Pharmacology

Background:

• Retinoid X receptors (RXRs) are crucial transcription factors with broad therapeutic potential.
• Current RXR agonists exhibit poor pharmacokinetic properties and adverse effects, limiting their clinical use.
• Developing improved RXR ligands is essential for unlocking their therapeutic benefits.

Purpose of the Study:

• To design and synthesize novel, potent, and pharmacokinetically improved RXR ligands.
• To overcome the limitations of existing RXR agonists, such as lipophilicity and adverse effects.
• To provide advanced chemical tools for exploring RXR's therapeutic potential.

Main Methods:

• Utilized oxaprozin as a scaffold for developing a new RXR ligand chemotype.
• Conducted systematic structure-activity relationship (SAR) analyses for structural optimization.
• Determined cocrystal structures of active derivatives to confirm binding mode.
• Performed in vivo profiling to assess pharmacokinetic properties and selectivity.

Main Results:

• Developed a novel chemotype with low nanomolar potency for RXR activation.
• Optimized compounds demonstrated superior pharmacokinetic properties compared to existing agonists.
• Cocrystal structures confirmed orthosteric binding of the new ligands.
• Demonstrated selective RXR activation and induction of RXR-regulated gene expression in vitro and in vivo.

Conclusions:

• The novel oxaprozin-based RXR ligands exhibit high potency and improved pharmacokinetic profiles.
• These compounds represent a promising new class of chemical tools for RXR research.
• Further exploration of these ligands may lead to new therapeutic strategies targeting RXR-mediated pathways.